Genentech Announces FDA Approval of XOFLUZA (Baloxavir Marboxil) for Influenza
Genentech Announces FDA Approval of XOFLUZA (Baloxavir Marboxil) for Influenza Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved XOFLUZA™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of [..]